The total pharmaceutical sales in the UK have experienced various fluctuations from 2013 to 2023. Sales peaked in 2021 at $30.94 billion followed by a noticeable decline in 2022, and a modest recovery into 2023 reaching $28.95 billion. The year-on-year variation displays both growth and contraction, with notable highs in 2014 (15.3%) and 2018 (8.55%), and lows in 2016 (-7.29%) and 2022 (-7.74%). The Compound Annual Growth Rate (CAGR) over the past five years from 2019 to 2023 stands at 1.2%.
Looking ahead, sales are anticipated to increase gradually, reaching $31.02 billion in 2028, with a forecasted CAGR of 0.96% over the next five years. This forecast indicates a stable yet modest growth trajectory for the UK pharmaceutical market.
Future trends to watch for include:
- Impact of new pharmaceutical regulatory changes post-Brexit
- Innovations in Biopharma and precision medicine
- Potential shifts in healthcare funding and policies
- Market entry of cheaper generic and biosimilar drugs
